Press Releases
June 19, 2006
June 19, 2006 PDF Version (24.1kb)
EPEIUS BIOTECHNOLOGIES CORPORATION RECEIVES $400,000 GRANT TO SUPPORT GENE THERAPY TRIALS FOR PANCREATIC CANCER.
SAN MARINO, California, June 19, 2006 - Epeius Biotechnologies Corporation announced today that the Company has been awarded a $400,000 grant by the Lazarex Cancer Foundation to expand and support ongoing cancer gene therapy clinical trials for advanced and metastatic pancreatic cancer. REXIN-G™ is the world's first targeted injectable gene therapy vector to be approved for use in clinical trials in the USA and abroad. When injected intravenously, REXIN-G™ seeks out and destroys metastatic cancer, without the systemic toxicity generally associated with chemotherapy. REXIN-G™ recently gained Orphan Drug status as an effective treatment for pancreatic cancer in the United States, and is currently available in clinical trials in Rochester MN. In a statement to the press, Ms. Dana Dornsife, President of the Lazarex Cancer Foundation said: "We are pleased to provide Epeius Biotechnologies Corporation the funds needed to expedite the development of such promising genetic medicines, which - by improving both the survival and the quality of life - provide cancer patients with more quality time."
MEDIA CONTACT:
Dr. Frederick L. Hall
President and CEO
Phone: 626-441-6695
Fax: 626-441-6692
Email: info@epeiusbiotech.com
You must have Adobe Acrobat Reader to view PDF files. You may download it for free by clicking here.